{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:57:31Z","timestamp":1784293051147,"version":"3.55.0"},"reference-count":15,"publisher":"Massachusetts Medical Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2023,8,24]]},"DOI":"10.1056\/nejmc2308155","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T21:02:02Z","timestamp":1692824522000},"page":"770-772","source":"Crossref","is-referenced-by-count":2,"title":["Medical and Public Health Imperatives of Xylazine"],"prefix":"10.1056","volume":"389","member":"150","reference":[{"key":"e_1_2_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2303120"},{"key":"e_1_2_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2022.2159427"},{"key":"e_1_3_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/vr.128.14.323"},{"key":"e_1_3_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb05505.x"},{"key":"e_1_3_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199809000-00005"},{"key":"e_1_3_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.08.038"},{"key":"e_1_4_3_2_2_2","first-page":"437","article-title":"Veterinary drugs: a new source of drug abuse?","volume":"96","author":"L\u00f3pez Briz E","year":"1991","unstructured":"L\u00f3pez Briz E, Barreda Aznar A, Guevara Serrano J, Blasco Mascar \u00c3. Veterinary drugs: a new source of drug abuse? Med Clin (Barc) 1991;96:437-437.2046436","journal-title":"Med Clin (Barc)"},{"key":"e_1_4_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563657908989878"},{"key":"e_1_4_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.287.6402.1369"},{"key":"e_1_4_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000955"},{"key":"e_1_5_3_2_2_2","unstructured":"Center for Forensic Science Research and Education. Fentanyl purity potency and synthesis: real-time testing of opioid drug products in the United States. August 16 2022 (https:\/\/www.cfsre.org\/nps-discovery\/drug-checking\/fentanyl-purity-potency-synthesis-real-time-testing-of-opioid-drug-products-in-the-united-states)."},{"key":"e_1_5_3_2_3_2","unstructured":"Philadelphia Department of Public Health. Health update: xylazine (tranq) exposure among people who use substances in Philadelphia. December 8 2022 (https:\/\/hip.phila.gov\/document\/3154\/PDPH-HAN_Update_13_Xylazine_12.08.2022.pdf\/)."},{"key":"e_1_5_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"e_1_5_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2022.2159427"},{"key":"e_1_5_3_2_6_2","unstructured":"White House Office of National Drug Control Policy. Fentanyl adulterated or associated with xylazine response plan. July 2023 (https:\/\/www.whitehouse.gov\/wp-content\/uploads\/2023\/07\/FENTANYL-ADULTERATED-OR-ASSOCIATED-WITH-XYLAZINE-EMERGING-THREAT-RESPONSE-PLAN-Report-July-2023.pdf)."}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMc2308155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T22:52:25Z","timestamp":1749682345000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMc2308155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,24]]}},"alternative-id":["10.1056\/NEJMc2308155"],"URL":"https:\/\/doi.org\/10.1056\/nejmc2308155","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]}}}